Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Revenue (2017 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Revenue for 14 consecutive years, with $805.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Revenue rose 28.33% year-over-year to $805.5 million, compared with a TTM value of $2.9 billion through Dec 2025, up 21.45%, and an annual FY2025 reading of $2.9 billion, up 21.45% over the prior year.
  • Revenue was $805.5 million for Q4 2025 at Neurocrine Biosciences, up from $794.9 million in the prior quarter.
  • Across five years, Revenue topped out at $805.5 million in Q4 2025 and bottomed at $15.0 million in Q2 2021.
  • Average Revenue over 4 years is $510.0 million, with a median of $515.3 million recorded in 2024.
  • The sharpest move saw Revenue crashed 95.04% in 2021, then soared 30.37% in 2024.
  • Year by year, Revenue stood at $296.0 million in 2021, then skyrocketed by 74.05% to $515.2 million in 2023, then grew by 21.84% to $627.7 million in 2024, then increased by 28.33% to $805.5 million in 2025.
  • Business Quant data shows Revenue for NBIX at $805.5 million in Q4 2025, $794.9 million in Q3 2025, and $687.5 million in Q2 2025.